Important problems in the diagnosis and treatment of autoimmune hepatitis (based on the Russian consensus 2017)


Cite item

Full Text

Abstract

The analysis of publications devoted to the Russian Consensus on the Diagnostic and Treatment of Autoimmune Hepatitis (AIH), which was considered at the 43rd annual Scientific Session of the CNIIG From Traditions to Innovation (March 4, 2017) is carried out. The presence of clear algorithms and recommendations for the diagnosis and treatment of AIH significantly help the doctor in real clinical practice, but do not exclude a personified approach to the patient.

About the authors

E V Vinnitskaya

S.A. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department

д.м.н., зав. отд. гепатологии МКНЦ им. А.С. Логинова

Yu G Sandler

S.A. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department

Email: sandlerjulia2012@gmail.com
к.м.н., с.н.с. гепатологического отд. МКНЦ им. А.С. Логинова

I G Bakulin

I.I. Mechnikov North-Western state medical University Ministry of Health of Russia

д.м.н., проф., СЗГМУ им. И.И. Мечникова

A I Parfenov

S.A. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department

д.м.н., проф., зав. отд. патологии кишечника МКНЦ им. А.С. Логинова

L Yu Ilchenko

N.I. Pirogov Russian National Research Medical University Ministry of Health of Russia

д.м.н., проф., РНИМУ им. Н.И. Пирогова

I G Nikitin

N.I. Pirogov Russian National Research Medical University Ministry of Health of Russia

д.м.н., проф., РНИМУ им. Н.И. Пирогова

A O Bueverov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)

д.м.н., проф., Первый МГМУ им. И.М. Сеченова

T N Lopatkina

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)

к.м.н., доц., Первый МГМУ им. И.М. Сеченова

T M Ignatova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)

V Ye Syutkin

N.V. Sklifosovskiy Research Institute of Emergency Medicine

д.м.н., проф., НИИ СП им. Н.В. Склифосовского

K L Raikhelson

Saint Petersburg state University

д.м.н., проф., СПбГУ

S G Khomeriki

S.A. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department

д.м.н., проф., зав. лаб. патоморфологии МКНЦ им. А.С. Логинова

R B Gudkova

S.A. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department

д.м.н., с.н.с. лаб. научно-диагностических исследований МКНЦ им. А.С. Логинова

References

  1. Ивашкин В.Т., Буеверов А.О., Маевская М.В., Абдулганиева Д.И. Клинические рекомендации по диагностике и лечению аутоиммунного гепатита. Российская Гастроэнтерологическая Ассоциация. Российское общество по изучению печени; 2013. Доступно по ссылке: http://www.gastro.ru/?pageId=41. Ссылка активна на 15.07.2017.
  2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015;63:971-1004. doi: 10.1016/j.jhep.2015.09.016
  3. Manns M.P, Czaja A.J, Gorham J.D, Krawitt E.L, Mieli-Vergani G, Vergani D, Vierling J.M. Diagnosis and Management of Autoimmune Hepatitis. AASLD Practice Guidelines. Hepatology. 2010;51(6):2193-213. doi: 10.1002/hep.23584
  4. Gleeson D, Heneghan M.A. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29. doi: 10.1136/gut.2010.235259
  5. Буеверов А.О. Серонегативный аутоиммуный гепатит. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):27-33. doi: 10.22416/1382-4376-2017-27-2-27-33.
  6. Dienes H.P, Erberich H, Dries V, Schirmacher P, Lohse A. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis. 2002;6:349-62.
  7. Czaja A.J, Carpenter H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34:659-65.
  8. Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol. 2007;38:1669-75. doi: 10.1016/j.humpath.2007.03.019
  9. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246-9. doi: 10.1136/ jcp.2005.029348
  10. Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone A.M, et al. Non - organ - specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2003;48:2173-81.
  11. Cotler S.J, Kanji K, Keshavarzian A, Jensen D.M, Jakate S. Prevalence and significance of autoantibodies in patients with non - alcoholic steatohepatitis. J Clin Gastroenterol. 2004;38:801-4.
  12. Wiegard C, Schramm C, Lohse A.W. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis. 2009;29:254-61. doi: 10.1002/hep.22322
  13. Luth S, Weiler-Normann C, Schramm C, Lohse A.W. Autoimmune liver diseases. Internist (Berl). 2009;50:310-7. doi: 10.1007/s001
  14. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99(8):1510-6.
  15. Luth S, Herkel J, Kanzler S, Frenzel C, Galle P.R, Dienes H.P, Schramm C, Lohse A.W. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42(8):926-30. doi: 10.1097/mcg.0b013e318154af74
  16. Czaja A.J. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver. 2016;10(2):177-203. doi: 10.5009/gnl15352
  17. Lohse A.W, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 2011;55(1):171-82. doi: 10.1016/j.jhep.2010.12.012
  18. Feld J.J, Dinh H, Arenovich T, Marcus V.A, Wanless I.R, Heathcote E.J. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53-62. doi: 10.1002/hep.20732
  19. Dufour J.F, Zimmermann M, Reichen J. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol. 2002;37:748-52.
  20. Czaja A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816-23. doi: 10.1111/j.1478-3231. 2008.01904.x
  21. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002;35:75-81.
  22. Лопаткина Т.Н. Аутоиммунный гепатит и перекрестные синдромы Фарматека. 2010;15(209):62-8.
  23. Manns M.P, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr M.J, Günther R, Hultcrantz R.W, Spengler U, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010; 139:1198-206. doi: 10.1053/j.gastro.2010.06.046
  24. Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, Strassburg CP, Prоls M, Woźniak M, Manns MP. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163:1347-453. doi: 10.1016/j.jpeds.2013.05.042
  25. Manns M.P, Bahr M.J, Woynarowski M, Kreisel W, Oren R, Gunther R, Hultcrantz R, Proels M, Rust C, Spengler U, et al. Budesonide 3 mg tid is superior to prednisone in combination with azathioprine in the treatment of autoimmune hepatitis. J Hepatol. 2008;2:369. doi: 10.1016/ S0168-8278(08)60991-5
  26. Manns M.P, Strassburg C.P. Therapeutic strategies for autoimmune hepatitis. Dig Dis. 2011;29(4):411-5. doi: 10.1159/000329805
  27. Czaja A.J. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315-30. doi: 10.1055/s-0029-1233530
  28. Czaja A.J, Carpenter H.A. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532-8.
  29. Czaja A.J. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008;25:219-39. doi: 10.2165/00002512-200825030-00005
  30. Al-Chalabi T, Boccato S, Portmann B.C, Mc Farlane I.G, Heneghan M.A. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45:575-83. doi: 10.1016/j.jhep.2006.04.007
  31. Strassburg C.P, Manns M.P. Autoimmune hepatitis in the elderly: What is the difference? J Hepatol. 2006;45(4):480-2. doi: 10.1016/ j.jhep.2006.07.008
  32. Terrabuio D.R, Abrantes-Lemos C.P, Carrilho F.J, Cancado E.L. Follow - up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol. 2009;43:350-6. doi: 10.1097/MCG.0b013e318176b8c5
  33. Schramm C, Herkel J, Beuers U, Kanzler S, Galle P.R, Lohse A.W. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol. 2006;101:556-60. doi: 10.1111/j.1572-0241.2006. 00479.x
  34. Westbrook R.H, Yeoman A.D, Kriese S, Heneghan M.A. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 2012;38:239-44. doi: 10.1016/j.jaut.2011.12.002
  35. Buchel E, van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare - up after delivery. Am J Gastroenterol. 2002;97:3160-5. doi: 10.1016/s0002-9270(02)05541-7
  36. Braga A.C, Vasconcelos C, Braga J. Pregnancy with autoimmune hepatitis. Gastroenterol Hepatol Bed Bench. 2016;9(3):224. doi: 10.1136/bcr-2015-212501
  37. De Boer N.K, Jarbandhan S.V, de Graaf P, Mulder C.J, van Elburg R.M, van Bodegraven A.A. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101:1390-2. doi: 10.1111/j.1572-0241.2006.00538
  38. Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Can Med Assoc J. 2011 Apr 19;183(7):796-804. doi: 10.1503/cmaj.101063
  39. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present D.H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9-17. doi: 10.1053/gast.2003.50014
  40. Werner M, Bjоrnsson E, Prytz H. Autoimmune hepatitis among fertile women: strategies during pregnancy and breast - feeding? Scand J Gastroenterol. 2007;42:986-91. doi: 10.1080/00365520601155266
  41. Akbari M, Shah S, Velayos F.S, Mahadevan U, Cheifetz A.S. Systematic review and meta - analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15-22. doi: 10.1002/ibd.22948
  42. Casanova M.J, Chaparro M, Domеnech E. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433-40. doi: 10.1038/ajg.2012.430
  43. Candia L, Marquez J, Espinoza L.R. Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma. Semin Arthritis Rheum. 2005;35:49-56.
  44. Bar J, Stahl B, Hod M, Wittenberg C, Pardo J, Merlob P. Is immunosuppression therapy in renal allograft recipients teratogenic? A single - center experience. Am J Med Genet A. 2003;116(1):31-6. doi: 10.1002/ajmg.a.10817
  45. Natekar A, Pupco A, Bosso P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Phys. 2011;57(12):1401-2.
  46. Naqvi R, Noor H, Ambareen S, Khan H, Haider A, Jafri N, et al. Outcome of pregnancy in renal allograft recipients: SIUT experience. Transplant Proc. 2006;38(7):2001-2. doi: 10.1016/j.transproceed. 2006.06.020
  47. Heneghan M.A, Norris S.M, O’Grady J.G, Harrison P.M, Mc Farlane I.G. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001;48:97-102.
  48. Goldstein L.H, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks M.E, Rost van Tonningen - van Driel M.M, Arnon J, Ornoy A, Clementi M, Di Gianantonio E, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007 Oct;79(10):696-701.
  49. Hutson J.R, Matlow J.N, Moretti M.E, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2012;33(1):1-8. doi: 10.3109/01443615. 2012.716106

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies